0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV45.21%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.46Leverage Ratio--Theta--Rho--Eff Leverage--Vega
MEI Pharma Stock Discussion
NEWS
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma, Inc. reports positive results from the ongoing Phase 1b study of ME-344 in combination with bevacizumab for relapsed metastatic colorectal cancer. 25% of patients had no disease progression at Week 16, exceeding the threshold to add more patients. The combination was well-tolerated, leading to the...
$Gossamer Bio(GOSS.US)$ $Starry Group(STRY.US)$ $Helbiz(HLBZ.US)$ $MEI Pharma(MEIP.US)$ $Digital Brands Group(DBGI.US)$ $Cosmos Health(COSM.US)$ $COMSovereign(COMS.US)$ $Mirati Therapeutics(MRTX.US)$ $United Parcel Service(UPS.US)$ $Sumo Logic(SUMO.US)$
wherr is thr link for earnings
Tomorrow to the 🚀🌕
https://www.etfdailynews.com/2022/05/02/mei-pharma-inc-nasdaqmeip-sees-significant-increase-in-short-interest/
Finally
No comment yet